Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 18, 2016
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
[ Fri, Nov 18th 2016
] - WOPRAI
Debjit Chattopadhyay Initiated (VRTX) at Hold and Held Target at $98 on, Nov 18th, 2016
Debjit Chattopadhyay of Janney Montgomery Scott, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold and Held Target at $98 on, Nov 18th, 2016.
Debjit has made no other calls on VRTX in the last 4 months.
There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 2 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrew Fein of "HC Wainwright & Co." Downgraded from Strong Buy to Hold on, Monday, October 24th, 2016
- Christopher Raymond of "Raymond James" Initiated at Hold on, Tuesday, September 13th, 2016
These are the ratings of the 2 analyists that currently disagree with Debjit
- Biren Amin of "Jefferies" Maintained at Strong Buy with Increased Target to $105 on, Wednesday, October 5th, 2016
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $139 on, Thursday, July 28th, 2016
